Testing a new lung cancer treatment versus standard care

Plain-English translation of NCT06868277 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Read our Carcinoma, Non-Small Cell Lung research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This is a large, global study testing whether a new medication called works better than (a standard immunotherapy) for treating advanced non-small cell lung cancer in patients whose tumors have a specific marker called PD-L1. About 830 people will participate. Neither you nor your doctor will know which treatment you receive until the study ends — both groups will be closely monitored to see how well the medication works and how safe it is.

Immunotherapy has helped many lung cancer patients, but researchers want to find even better options. This medication is being tested to see if it can work more effectively than current standard treatments for this type of advanced lung cancer.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced (stage IV) non-small cell lung cancer that cannot be cured with surgery or radiation
your tumor has the PD-L1 marker and does not have certain genetic mutations (EGFR, ALK, or ROS1) that would make you eligible for other targeted therapies
you are in good enough health to participate, with a life expectancy of at least 12 weeks
you have not received any previous chemotherapy or immunotherapy treatments for advanced lung cancer
you have measurable tumors visible on imaging scans that can be accurately tracked throughout the study

You likely don't qualify if…

you have untreated or symptomatic brain metastases (cancer that has spread to the brain)
you have a history of autoimmune disease or are taking chronic steroid medications that suppress your immune system
you have received previous treatment with anti-PD-1 or anti-PD-L1 immunotherapies, or other checkpoint inhibitor therapies
you have an active infection, tuberculosis, or active immune deficiency disorder
you have had an organ transplant in the past

What participation looks like

You will be randomly assigned to receive either the new medication or the standard treatment — neither you nor your doctor will know which one you're getting. You'll visit the clinic regularly for check-in appointments, blood tests, and imaging scans to monitor how well the treatment is working and to check for any side effects. The study will continue for as long as the treatment is helping you and you're tolerating it well.

AI-generated summary from trial data · Jun 30, 2026 · Not medical advice

Trial locations(296 sites)

United States

Research Site, La Mesa, California

Research Site, Los Alamitos, California

Research Site, Farmington, Connecticut

Research Site, Newark, Delaware

Research Site, Bay Pines, Florida